Amy Vaughan, MD
Dermatology · Barboursville, WVNPI 1073503223
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $16,166 of the $23,924 with a category attached, or 67.6%. AbbVie accounts for 83.8% of it on its own, with 22 other manufacturers making up the rest. Among dermatology clinicians in WV with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 497 payments — averaging $48.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$20K
- Johnson & Johnson$619
- Galderma Laboratories, L.p.$516
- Merz North America, Inc.$512
- Regeneron Healthcare Solutions, Inc.$488
- E.r. Squibb & Sons, L.L.C.$446
- plus $1K from 17 others
What the payments were for
- Speaking & faculty fees$16,16668%
- Food & beverage$7,37031%
- Education$3872%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 313 | $20,038 |
| Johnson & Johnson | 38 | $619 |
| Galderma Laboratories, L.p. | 29 | $516 |
| Merz North America, Inc. | 5 | $512 |
| Regeneron Healthcare Solutions, Inc. | 17 | $488 |
| E.r. Squibb & Sons, L.L.C. | 31 | $446 |
| Novartis | 19 | $381 |
| Lilly USA, LLC | 15 | $271 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $112 |
| Dermavant Sciences, Inc. | 3 | $97 |
| Sun Pharmaceutical Industries Inc. | 2 | $91 |
| Pfizer | 4 | $68 |
| Arcutis Biotherapeutics, Inc. | 3 | $53 |
| Hill Dermaceuticals, Inc. | 2 | $46 |
| Organon | 2 | $33 |
| LEO Pharma Inc. | 1 | $29 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 2 | $27 |
| GSK | 1 | $19 |
| Dermira, Inc. | 1 | $18 |
| Genentech USA, Inc. | 1 | $17 |
| Janssen Scientific Affairs, LLC | 1 | $15 |
| Incyte Corporation | 1 | $15 |
| Amgen | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BOTOX$233
How this compares
$23,924 in reported general payments places this provider in the 90th percentile of 39 dermatology providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SkyriziRisankizumab-Rzaa | 29 | $596,986 |
| Dupixent SyringeDupilumab | 44 | $172,154 |
| Taltz AutoinjectorIxekizumab | 11 | $77,940 |
| BotoxOnabotulinumtoxina | 11 | $7,160 |
| Fluorouracil | 74 | $4,950 |
| Clobetasol Propionate | 70 | $4,895 |
| Metronidazole | 47 | $3,981 |
| Desonide | 14 | $2,089 |
| Doxycycline Hyclate | 93 | $1,464 |
| Tretinoin | 13 | $1,132 |
| Clindamycin Phosphate | 21 | $1,005 |
| Triamcinolone Acetonide | 41 | $676 |
| Ketoconazole | 36 | $670 |
| Spironolactone | 31 | $548 |
| Hydroxychloroquine Sulfate | 26 | $485 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieSkyrizi, Botox | $20,038 | $604,14640 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 39 dermatology providers in West Virginia.
Other dermatology in Barboursville
- Charles FranzBridgeport$728K
- Rola GharibMorgantown$393K
- Kenneth HardyMorgantown$13K
- Gregory LagosSouth Charleston$11K
- Suresh MenonMartinsburg$11K
- Jeffrey DodsonBridgeport$10K
- Sharifeh FarasatBridgeport$9K
- Thomas KarrsRonceverte$8K
- Susan ToumaHuntington$6K
- Michele MaouadMorgantown$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.